+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

P

Actively Recruiting

Healthy Volunteer

This research aims to evaluate the safety and tolerability of a second dose of the RSVpreF vaccine given during later pregnancies and to study how long immunity lasts from a single dose administered during a previous pregnancy. The study includes pregnant participants and their unborn babies as well as nonpregnant participants who previously received the vaccine. It is a Phase 3 trial focusing on prevention of RSV infection. Pregnant participants are divided into two groups those with previous antibody data who will receive a second dose of RSVpreF, and those without such data who will be randomly assigned to receive either RSVpreF or a placebo. Infants born to these participants will be monitored for safety and antibody levels up to six months after birth. Nonpregnant participants who received RSVpreF during an earlier pregnancy will have blood samples taken to assess the persistence of their immune response but will not receive any vaccine during this study. Participants will undergo safety assessments including monitoring for local and systemic reactions, adverse events, and serious adverse events after vaccination. Infant safety and antibody levels will also be closely observed. Blood samples will measure neutralizing antibodies at birth and at three and six months. The study involves informed consent and follows participants through pregnancy, birth, and postnatal periods up to six months for infants, with the total study duration extending to February 2028.

Age: 0Years +All GendersPhase 3
97 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, reactogenicity, and immune response of the GlaxoSmithKline Biologicals SA GSK Vaccines Institute for Global Health GVGH invasive nontyphoidal Salmonella-typhoid conjugate iNTS-TCV vaccine in infants. The study focuses on administering the first dose either at 6 months of age or at 6 weeks of age. This Phase 2a trial aims to find the appropriate dose and schedule for the vaccine to protect against invasive nontyphoidal Salmonella disease and typhoid fever in infants in Africa. The study involves multiple groups of infants receiving different vaccine schedules and doses. Infants aged 6 months receive three doses of either a low or full dose of iNTS-TCV vaccine on Day 1, Day 85, and Day 337, or combinations of other vaccines including TYPHIBEV, Prevenar 13, and Nimenrix. Infants aged 6 weeks receive similar dosing schedules but with adjusted timing at Day 1, Day 57, and Day 232, including some groups receiving saline doses. The study includes control groups receiving licensed vaccines for comparison. Participants will be closely monitored throughout the study for side effects at the injection site and systemically, with assessments occurring within 7 days after each vaccine dose. Safety monitoring continues for up to 505 days for infants starting at 6 months and 400 days for those starting at 6 weeks. Blood tests will measure immune responses before and after vaccinations, evaluating antibodies against Salmonella and typhoid antigens. The study includes detailed laboratory assessments and tracking of any adverse events or serious complications during the follow-up period.

Age: 6Weeks - 6MonthsAll GendersPhase 2
1 location
L

Actively Recruiting

Healthy Volunteer

Researchers are studying the persistence of immune response to the NmCV-5 vaccine, a pentavalent meningococcal ACYWX conjugate vaccine, in participants aged 2 to 29 years from Mali and The Gambia. The goal is to understand how long the antibody protection lasts more than five years after a single dose vaccination and whether a booster dose might be needed in this population. This observational long-term follow-up study involves contacting 1800 former participants from an earlier study by phone, followed by an in-person visit for a randomly selected subset of 450 participants. The study focuses on evaluating antibody levels against meningococcal serogroups A, C, Y, W, and X more than five years post-vaccination, measuring geometric mean titers and percentages of participants with specific antibody titers. Participants will be involved in a telephone interview and a clinical visit for blood sampling to assess antibody levels. Researchers will measure immune response persistence using serum bactericidal antibody titers. The study will monitor these immune markers to help determine the duration of vaccine-induced protection. Participation will last beyond five years after the initial vaccination, with safety and compliance monitored throughout.

Age: 7Years - 36YearsAll Genders
2 locations